Live Earnings Conference Call: SOPHiA GENETICS's Q2 2025 earnings call is happening now. Follow this link to listen to the live Q2 2025 earnings call for SOPHiA GENETICS. Listen live. NASDAQ:SOPH SOPHiA GENETICS (SOPH) Stock Price, News & Analysis $3.30 +0.14 (+4.43%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$3.06 -0.25 (-7.42%) As of 08:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About SOPHiA GENETICS Stock (NASDAQ:SOPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SOPHiA GENETICS alerts:Sign Up Key Stats Today's Range$3.22▼$3.5650-Day Range$2.86▼$3.7552-Week Range$2.58▼$4.92Volume104,927 shsAverage Volume35,666 shsMarket Capitalization$220.08 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingModerate Buy Company Overview SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. Read More SOPHiA GENETICS Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreSOPH MarketRank™: SOPHiA GENETICS scored higher than 33% of companies evaluated by MarketBeat, and ranked 1509th out of 1,836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingSOPHiA GENETICS has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageSOPHiA GENETICS has received no research coverage in the past 90 days.Read more about SOPHiA GENETICS's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for SOPHiA GENETICS are expected to grow in the coming year, from ($0.96) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SOPHiA GENETICS is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SOPHiA GENETICS is -3.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSOPHiA GENETICS has a P/B Ratio of 2.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about SOPHiA GENETICS's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.07% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently increased by 123.75%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSOPHiA GENETICS does not currently pay a dividend.Dividend GrowthSOPHiA GENETICS does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.07% of the float of SOPHiA GENETICS has been sold short.Short Interest Ratio / Days to CoverSOPHiA GENETICS has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SOPHiA GENETICS has recently increased by 123.75%, indicating that investor sentiment is decreasing significantly. News and Social Media0.8 / 5News Sentiment-0.50 News SentimentSOPHiA GENETICS has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for SOPHiA GENETICS this week, compared to 2 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SOPHiA GENETICS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.88% of the stock of SOPHiA GENETICS is held by insiders.Percentage Held by InstitutionsOnly 31.59% of the stock of SOPHiA GENETICS is held by institutions.Read more about SOPHiA GENETICS's insider trading history. Receive SOPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter. Email Address SOPH Stock News HeadlinesSOPHiA GENETICS Reports Financial Results for Mid-20252 hours ago | tipranks.comSOPHiA GENETICS Reports Second Quarter 2025 Results3 hours ago | prnewswire.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...August 5 at 2:00 AM | InvestorPlace (Ad)SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes3 hours ago | prnewswire.comSOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025July 22, 2025 | prnewswire.comM42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, careJune 3, 2025 | msn.comHigh Court grants custody of IVF baby to adoptive, not biological parentsMay 12, 2025 | msn.comSOPHiA GENETICS First Quarter 2025 Earnings: Revenues Beat Expectations, EPS LagsMay 12, 2025 | uk.finance.yahoo.comSee More Headlines SOPH Stock Analysis - Frequently Asked Questions How have SOPH shares performed this year? SOPHiA GENETICS's stock was trading at $3.07 at the beginning of 2025. Since then, SOPH shares have increased by 7.5% and is now trading at $3.30. How were SOPHiA GENETICS's earnings last quarter? SOPHiA GENETICS SA (NASDAQ:SOPH) released its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.05. The business earned $17.78 million during the quarter, compared to analysts' expectations of $16.76 million. SOPHiA GENETICS had a negative trailing twelve-month return on equity of 63.47% and a negative net margin of 98.51%. Read the conference call transcript. When did SOPHiA GENETICS IPO? SOPHiA GENETICS (SOPH) raised $234 million in an IPO on Friday, July 23rd 2021. The company issued 13,000,000 shares at a price of $17.00-$19.00 per share. Who are SOPHiA GENETICS's major shareholders? Top institutional shareholders of SOPHiA GENETICS include Silverberg Bernstein Capital Management LLC (0.07%), Green Alpha Advisors LLC (0.06%) and Ridgewood Investments LLC (0.05%). How do I buy shares of SOPHiA GENETICS? Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SOPHiA GENETICS own? Based on aggregate information from My MarketBeat watchlists, some other companies that SOPHiA GENETICS investors own include Occidental Petroleum (OXY), PayPal (PYPL), Chesapeake Energy (CHK), Cheniere Energy (LNG), Rocket Pharmaceuticals (RCKT), AbCellera Biologics (ABCL) and Farmers & Merchants Bancorp (FMAO). Company Calendar Last Earnings5/06/2025Today8/05/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SOPH CIK1840706 Webwww.sophiagenetics.com Phone41-21-694-1060FaxN/AEmployees520Year FoundedN/APrice Target and Rating Average Price Target for SOPHiA GENETICS$7.00 High Price Target$11.00 Low Price Target$5.00 Potential Upside/Downside+112.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$62.49 million Net Margins-98.51% Pretax Margin-96.41% Return on Equity-63.47% Return on Assets-40.06% Debt Debt-to-Equity Ratio0.16 Current Ratio3.11 Quick Ratio2.94 Sales & Book Value Annual Sales$65.17 million Price / Sales3.38 Cash FlowN/A Price / Cash FlowN/A Book Value$1.48 per share Price / Book2.23Miscellaneous Outstanding Shares66,690,000Free Float63,433,000Market Cap$220.08 million OptionableNot Optionable Beta1.00 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:SOPH) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWall Street Hates This Gold IRA Strategy—Here’s WhyWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SOPHiA GENETICS SA Please log in to your account or sign up in order to add this asset to your watchlist. Share SOPHiA GENETICS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.